Anti-Dopamine Receptor D1 (DRD1) antibodies help assess neuro-immune activity linked to PANS/PANDAS and autoimmune effects on dopamine signaling.
Autoimmune Brain Panel™ (formerly Cunningham Panel™)
The Autoimmune Brain Panel™—commonly known as the Cunningham Panel™—is a specialized neuro-immune test designed to measure autoantibodies and cell-signaling activity associated with PANS, PANDAS, Sydenham chorea, and other neuropsychiatric conditions linked to immune dysregulation.
This panel evaluates whether the immune system is producing antibodies that may mistakenly target neuronal tissue, particularly structures involved in movement, behavior, mood, memory, and executive function. These autoantibodies can influence dopamine signaling and activate intracellular pathways, potentially contributing to sudden-onset symptoms such as OCD, anxiety, tics, mood changes, or cognitive decline.
The panel includes five biomarkers:
-
Anti-Dopamine Receptor D1 (DRD1)
-
Anti-Dopamine Receptor D2L (DRD2L)
-
Anti-Lysoganglioside GM1
-
Anti-Tubulin
-
CaM Kinase II (CaMKII) activation
Together, these markers help identify immune-mediated disruption of neuronal signaling, a pattern observed in autoimmune neuropsychiatric disorders. While this panel does not diagnose PANS/PANDAS on its own, it offers meaningful supportive evidence when interpreted with clinical symptoms, history of infection, and other immune markers such as ASO and anti-DNase B.
Because the reference ranges are derived largely from pediatric controls, interpretation must be done in the context of age, symptoms, and clinical assessment.
This panel is performed exclusively by Moleculera Labs, a CLIA-certified laboratory specializing in neuro-immune diagnostics.
Biomarkers in this category
5 biomarkers · optimal ranges shown
Anti-Dopamine Receptor D2L antibodies help assess neuro-immune activity affecting dopamine pathways, often linked to PANS, PANDAS, and autoimmune brain disorders.
Anti-Lysoganglioside GM1 antibodies help assess neuro-immune activity affecting nerve cells, commonly associated with PANS, PANDAS, and autoimmune brain disorders.
Anti-Tubulin antibodies help assess neuro-immune activity that may affect neuronal structure and signaling, often associated with PANS, PANDAS, and autoimmune brain disorders.
CaM Kinase II (CaMKII) measures immune effects on neuronal signaling and helps evaluate neuro-immune conditions such as PANS, PANDAS, and autoimmune brain disorders.